Twist Bioscience (TWST) Operating Expenses (2017 - 2026)

Twist Bioscience (TWST) has reported Operating Expenses for 10 consecutive years, with $156.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 16.54% year-over-year to $156.6 million; the TTM figure through Mar 2026 stood at $548.3 million (changed 0.1% YoY), while the FY2025 annual figure was $512.8 million, down 3.93% from the prior year.
• Operating Expenses rose to $156.6 million in Q1 2026 per TWST's latest filing, from $136.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $170.4 million in Q2 2024 and bottomed at $98.9 million in Q4 2022.
• Historically, Operating Expenses has averaged $126.0 million across 5 years, with a median of $123.4 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 57.39% — and 2025, when it slipped 25.95%.
• Twist Bioscience's Operating Expenses stood at $98.9 million in 2022, then advanced by 19.83% to $118.5 million in 2023, then grew by 4.12% to $123.4 million in 2024, then climbed by 10.73% to $136.6 million in 2025, then gained by 14.63% to $156.6 million in 2026.
• Business Quant data shows TWST's Operating Expenses at $156.6 million in Q1 2026, $136.6 million in Q4 2025, and $128.9 million in Q3 2025.